Nephrologie & therapeutique最新文献_第9页

Once upon a time in nephrology - Episode 1: Management of thrombotic microangiopathy 曾几何时在肾脏病-第1集：血栓性微血管病的管理

Nephrologie & therapeutique Pub Date : 2025-06-27 DOI: 10.1684/ndt.2025.128

Simon Ville, Pierre Delanaye, Christophe Mariat

引用次数: 0

Once upon a time in nephrology, or how did we get here? 从前在肾脏学，或者我们是怎么走到这一步的？

Nephrologie & therapeutique Pub Date : 2025-06-27 DOI: 10.1684/ndt.2025.126

Simon Ville, Pierre Delanaye, Christophe Mariat

引用次数: 0

Effectiveness of virtual reality interventions on anxiety and depressive symptoms in hemodialysis patients: A systematic review 虚拟现实干预对血液透析患者焦虑和抑郁症状的有效性：系统综述

IF 0.7

Nephrologie & therapeutique Pub Date : 2025-06-27 DOI: 10.1684/ndt.2025.122

Safia Mecerli, Valentine Cazauvieilh, Romain Vial, Sébastien Colson, Christophe Roman, Mickaël Bobot, Philippe Brunet

{"title":"Effectiveness of virtual reality interventions on anxiety and depressive symptoms in hemodialysis patients: A systematic review","authors":"Safia Mecerli, Valentine Cazauvieilh, Romain Vial, Sébastien Colson, Christophe Roman, Mickaël Bobot, Philippe Brunet","doi":"10.1684/ndt.2025.122","DOIUrl":"10.1684/ndt.2025.122","url":null,"abstract":"Background: End-stage chronic kidney disease affects millions of people worldwide, and its treatment through hemodialysis results in a high rate of depression and anxiety. To address these disorders, virtual reality can be used as a non-pharmacological psychological intervention.Objective: To describe the effectiveness of virtual reality interventions on depression and anxiety symptoms in hemodialysis patients.Methods: A systematic review was conducted in the PubMed, Embase, ScienceDirect, and PsycInfo databases. Six quantitative studies published between 2019 and 2024 that address the impact of virtual reality on anxiety and depressive symptoms in hemodialysis patients were included according to the PRISMA method. A methodical analysis of these studies was performed.Results: These studies utilize various virtual reality interventions, both immersive and non-immersive, such as “exergaming.” They predominantly report a significant improvement in depression and anxiety scores in hemodialysis patients. The benefit of these studies varies according to the type and duration of the intervention. The main limitations include the small number of available studies and limited sample sizes.Conclusion: Virtual reality interventions show promising potential for improving anxiety and depressive symptoms in hemodialysis patients. They can find a place in non-pharmacological management. Large additional studies are needed to better understand their potential benefits and to optimize their handling by patients and caregivers.","PeriodicalId":94153,"journal":{"name":"Nephrologie & therapeutique","volume":"21 3","pages":"170-179"},"PeriodicalIF":0.7,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144268290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biopsy-based transcriptomics in kidney transplantation: Where do we stand in 2025? 肾脏移植中的分子生物学工具用于诊断排斥反应。2025年我们在哪里？

IF 0.7

Nephrologie & therapeutique Pub Date : 2025-06-27 DOI: 10.1684/ndt.2025.125

Rachna Baguant, Dominique Bertrand, Arnaud François, Steven Grangé, Dominique Guerrot, Charlotte Laurent, Mathilde Lemoine, Sophie Candon, Tristan de Nattes

{"title":"Biopsy-based transcriptomics in kidney transplantation: Where do we stand in 2025?","authors":"Rachna Baguant, Dominique Bertrand, Arnaud François, Steven Grangé, Dominique Guerrot, Charlotte Laurent, Mathilde Lemoine, Sophie Candon, Tristan de Nattes","doi":"10.1684/ndt.2025.125","DOIUrl":"10.1684/ndt.2025.125","url":null,"abstract":"Despite advances in the physiopathological understanding of kidney transplantation immunology, kidney transplant rejection remains the leading cause of allograft loss. The current gold standard for diagnosing rejection is histological assessment of kidney transplant biopsies.\u0000Biopsy-based transcriptomics have been the subject of numerous studies, enabling the analysis of hundreds of transcripts expressed in biopsy samples. These tools allow for the identification of new pathophysiological pathways, providing a better understanding of rejection and potentially revealing therapeutic targets.\u0000Biopsy-based transcriptomics may also improve the diagnosis of rejection, in particular antibody-mediated rejection. However, the use of these tools in routine practice is limited due to restricted availability, the challenge of interpreting data from hundreds of transcripts without clear guidelines, and their cost. In addition, due to the limited accessibility of molecular tools, their exact impact on patient management has not yet been determined.\u0000This update provides an overview of biopsy-based transcriptomics in 2025, focusing on the limitations of current diagnostic methods for rejection, the molecular biology tools available, and their use in clinical practice.","PeriodicalId":94153,"journal":{"name":"Nephrologie & therapeutique","volume":"21 2","pages":"184-194"},"PeriodicalIF":0.7,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144268289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Are your kidneys ok? Early detection to protect kidney health. 你的肾脏还好吗？早期发现，保护肾脏健康。

Nephrologie & therapeutique Pub Date : 2025-05-15 DOI: 10.1684/ndt.2025.120

Joseph A Vassalotti, Anna Francis, Augusto Cesar Soares Dos Santos, Ricardo Correa-Rotter, Dina Abdellatif, Li-Li Hsiao, Stefanos Roumeliotis, Agnes Haris, Latha A Kumaraswami, Siu-Fai Lui, Alessandro Balducci, Vassilios Liakopoulos

{"title":"Are your kidneys ok? Early detection to protect kidney health.","authors":"Joseph A Vassalotti, Anna Francis, Augusto Cesar Soares Dos Santos, Ricardo Correa-Rotter, Dina Abdellatif, Li-Li Hsiao, Stefanos Roumeliotis, Agnes Haris, Latha A Kumaraswami, Siu-Fai Lui, Alessandro Balducci, Vassilios Liakopoulos","doi":"10.1684/ndt.2025.120","DOIUrl":"10.1684/ndt.2025.120","url":null,"abstract":"Early detection of kidney disease can protect kidney health, prevent kidney disease progression and related complications, reduce the risk of cardiovascular disease, and decrease mortality. We must ask, “Are your kidneys ok?” by using serum creatinine to estimate kidney function and urine albumin to assess kidney and endothelial damage. Evaluation of causes and risk factors for chronic kidney disease (CKD) includes testing for diabetes, as well as measuring blood pressure and body mass index. This World Kidney Day we assert that case-finding in high-risk populations – or even population-level screening – can significantly reduce the global burden of kidney disease. Early-stage CKD is asymptomatic and simple to test for. Recent paradigm-shifting CKD treatments, such as sodium-glucose cotransporter-2 inhibitors, dramatically improve outcomes and favor the cost-benefit analysis for screening or case-finding programs. Despite this, numerous barriers exist, including resource allocation, health care funding, infrastructure, and both health care professionals’ and the public’s awareness of kidney disease. Coordinated efforts by major kidney-focused non-governmental organizations to prioritize kidney health within government agendas and align early detection efforts with other current programs will maximize efficiencies.","PeriodicalId":94153,"journal":{"name":"Nephrologie & therapeutique","volume":"21 2","pages":"65-72"},"PeriodicalIF":0.0,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144083039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Physical activity in hemodialysis 血液透析中的体力活动

Nephrologie & therapeutique Pub Date : 2025-05-15 DOI: 10.1684/ndt.2025.116

Quentin Bellanger, Antoine Desvergée, Mélanie Hanoy, Hélène Azambourg, Nicolas Gautier, Patrick Henri

引用次数: 0

Intradialytic parenteral nutrition: theory and practical application 肠外营养：理论与实际应用

Nephrologie & therapeutique Pub Date : 2025-05-15 DOI: 10.1684/ndt.2025.117

Céline Pasian, Raymond Azar, Denis Fouque, Laetitia Koppe, Fitsum Guebre-Egziabher, Frédéric V Valla, Stanislas Trolonge, Philippe Chauveau, Céline Nodimar, Laura Brien, Stanislas Bataille

引用次数: 0

The highlights of kidney transplantation in 2024 2024年肾移植的亮点

Nephrologie & therapeutique Pub Date : 2025-04-10 DOI: 10.1684/ndt.2025.111

Thomas Jouve

引用次数: 0

The highlights of nephrology in 2024 2024年肾脏病学的亮点

Nephrologie & therapeutique Pub Date : 2025-04-10 DOI: 10.1684/ndt.2025.110

Camille Cohen

{"title":"The highlights of nephrology in 2024","authors":"Camille Cohen","doi":"10.1684/ndt.2025.110","DOIUrl":"10.1684/ndt.2025.110","url":null,"abstract":"The year 2024 marks significant progress in nephrology, particularly in immunoglobulin A (IgA) nephropathy and nephroprotection. In IgA nephropathy, new molecules such as sibeprenlimab and atacicept, targeting the BAFF and APRIL pathways, have shown a reduction in proteinuria and stabilization of glomerular filtration rate (GFR), confirming the importance of these pathways in the disease. Furthermore, the involvement of the microbiota in the pathology opens up promising therapeutic prospects. In nephroprotection, the combination of SGLT2 inhibitors, endothelin receptors and GLP1 agonists enhances the management of chronic kidney disease, including diabetic nephropathy, with positive effects on proteinuria and renal survival. The discovery of anti-nephrin antibodies in idiopathic nephrotic syndrome (INS) marks a major step forward, enabling better prediction of the response to immunosuppressants and a more refined diagnosis between autoimmune and genetic pathologies, and opening up the future prospect of more personalized management of this pathology. Derived from hematology, anti-CD38 therapies are also showing promising results in glomerulopathies, while CAR-T cells are opening the way to new therapeutic options for refractory autoimmune diseases such as lupus. These advances testify to a move towards precision medicine in nephrology, where the personalization of treatments could, in time, significantly improve the management of patients with kidney pathologies.","PeriodicalId":94153,"journal":{"name":"Nephrologie & therapeutique","volume":"21 S1","pages":"5-10"},"PeriodicalIF":0.0,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144039875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The highlights of dialysis in 2024 2024年透析的亮点

Nephrologie & therapeutique Pub Date : 2025-04-10 DOI: 10.1684/ndt.2025.112

Sébastien Rubin

{"title":"The highlights of dialysis in 2024","authors":"Sébastien Rubin","doi":"10.1684/ndt.2025.112","DOIUrl":"10.1684/ndt.2025.112","url":null,"abstract":"In 2024, dialysis is experiencing advancements, particularly in environmental sustainability. “Green dialysis” is emerging as a priority, aiming to reduce the carbon footprint of dialysis centers (water and resource consumption, patient transportation). Innovative strategies, such as adjusting dialysate flow rate and temperature, have demonstrated similar effectiveness to standard dialysis in terms of Kt/V while reducing water consumption. A recent Cochrane review confirms the equivalence between peritoneal dialysis (PD) and hemodialysis (HD) in terms of mortality. Additionally, hemodiafiltration (HDF) is regaining attention thanks to the CONVINCE study and its ancillary studies, which show a reduction in mortality risk and an improvement in quality of life. Furthermore, technical adaptations are making HDF more environmentally friendly. Anticoagulation strategies are also evolving: heparin-free dialysis, using calcium-free dialysate and reinjection controlled by ionic dialysance, has proven effective. A large French study based on the Rein registry and the National Health Data System database shows that direct oral anticoagulants, particularly apixaban, although not officially approved for dialysis (off-label use), offer promising prospects for reducing thromboembolic risk. Chronic inflammation, a major cardiovascular risk factor in dialysis patients, is the focus of therapeutic trials targeting IL-6 (clazakizumab), with encouraging phase II results. Meanwhile, dialysate sodium management is being reassessed: individualized reductions can help better control blood pressure but must be used cautiously in certain patients. Finally, in elderly patients contraindicated for transplantation, initiating hemodialysis provides only a modest survival benefit, sometimes at the cost of reduced time spent at home. Decisions between dialysis and conservative management (opting not to dialyze) should therefore be guided by patient preferences and quality of life.","PeriodicalId":94153,"journal":{"name":"Nephrologie & therapeutique","volume":"21 S1","pages":"11-17"},"PeriodicalIF":0.0,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144048497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0